Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials

Diabetes, Obesity and Metabolism

Volumn 19, Issue 7, 2017, Pages 926-935

  Neal, Bruce ^a,b,c,d   Perkovic, Vlado ^a,e   Mahaffey, Kenneth W ^f   Fulcher, Greg ^e   Erondu, Ngozi ^g   Desai, Mehul ^g   Shaw, Wayne ^g   Law, Gordon ^g   Walton, Marc K ^g   Rosenthal, Norm ^g   de Zeeuw, Dick ^h   Matthews, David R ⁱ  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cardiovascular disease; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DATA PROCESSING; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; POSTMARKETING SURVEILLANCE; PROCESS OPTIMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STUDY DESIGN; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MONITORING; EQUIVALENCE TRIAL (TOPIC); FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK FACTOR;

AGED; BIOMARKERS; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; EQUIVALENCE TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MORTALITY; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020470639     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12924     Document Type: Article

References (18)

1. Janssen Research & Development, LLC. Endocrinologic and Metabolic Drugs Advisory Committee. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. JNJ-28431754 (Canagliflozin). NDA 204042. January 10, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf. Accessed December 21, 2016.
2. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.
3. Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(3):387-393.
4. Janssen Research & Development, LLC. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). ClinicalTrials.gov Identifier: NCT02065791. February 17, 2014. https://clinicaltrials.gov/ct2/show/NCT02065791. Accessed December 19, 2016.
5. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411-419.
6. Cohen D. Rosiglitazone: what went wrong? BMJ. 2010;341:c4848.
7. US Food and Drug Administration. Guidance for industry diabetes mellitus – Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071627.pdf. Accessed December 19, 2016.
8. US Food and Drug Administration. FDA Briefing Document. NDA 204042. Invokana (canagliflozin) tablets. Applicant: Janssen Pharmaceuticals, Inc. Endocrinologic and metabolic drugs advisory Committee Meeting. January 10, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed December 19, 2016.
9. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6(3):289-302.
10. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-411.
11. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680-1686.
12. US Food and Drug Administration. Invokana and Invokamet (canagliflozin): drug safety communication—new information on bone fracture risk and decreased bone mineral density. September 10, 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm. Accessed November 11, 2015.
13. FARXIGA® (dapagliflozin) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016.
14. US Food and Drug Administration. FDA Drug Safety Communication: interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. May 18, 2016. http://www.fda.gov/Drugs/DrugSafety/ucm500965.htm. Accessed July 22, 2016.
15. European Medicines Agency. SGLT2 inhibitors (previously canagliflozin) Article-20 procedure – PRAC concludes that diabetes medicine canagliflozin may contribute to risk of toe amputation. February 10, 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors_(previously_Canagliflozin)/human_referral_prac_000059.jsp&mid=WC0b01ac05805c516f. Accessed February 15, 2017.
16. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
17. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
18. Babre D. Medical coding in clinical trials. Persp Clin Res. 2010;1(1):29-32.